Aviado · Research
Longevity Daily
Monday, August 10, 2026
Listen
Today's Brief
A landmark Lancet Commission report finds that nearly 45% of dementia cases are preventable through 14 modifiable lifestyle factors — making brain protection today's most actionable longevity story. The first clinical trial to combine rapamycin and exercise takes on a question every biohacker has been asking, while Robb Report's deep dive on Klotho separates signal from hype on longevity's buzziest protein. We also take a hard look at Neuriva's evidence base, explore the psychological costs of extreme health optimization, and track NMN's march toward a $1 billion market.
10 stories2 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Nearly Half of All Dementia Cases Are Preventable, New Lancet Commission Report Finds
A sweeping new Lancet Commission report identifies 14 modifiable risk factors — including hearing loss, high blood pressure, physical inactivity, obesity, smoking, depression, social isolation, and air pollution — that together account for nearly 45% of dementia cases worldwide. Crucially, the study found that risk factor profiles differ significantly by country and income level, meaning there is no single prevention formula, but the opportunity to reduce risk exists virtually everywhere. Hearing protection and early cardiovascular management emerged as among the highest-leverage interventions. If you do nothing else after reading this, schedule a blood pressure check — and start protecting your ears.
Read more →An Alzheimer's Expert Names the 6 Habits He Avoids to Protect His Brain
Dr. David Perlmutter breaks down six behaviors he avoids to protect cognitive health, with hearing neglect ranking surprisingly high alongside the usual suspects — poor sleep, sedentary behavior, and chronic stress. Hearing loss is now recognized as one of the most impactful modifiable dementia risk factors, yet most people ignore it until damage is done. Worth bookmarking as a practical checklist, and worth sharing with anyone who still thinks brain health is just about doing crossword puzzles.
Read more →Supplements & Compounds
The First Clinical Trial to Combine Rapamycin and Exercise Has Launched
Rapamycin suppresses mTOR — the cellular growth pathway that, when dialed down, extends lifespan across multiple species — but mTOR is also essential for muscle protein synthesis, raising a real concern that rapamycin might blunt the gains from resistance training. The first clinical trial to put both interventions in the same protocol is now underway, directly testing that tension. The results could reshape how longevity-focused athletes think about stacking mTOR inhibitors with a serious fitness routine.
Read more →Neuriva Is One of America's Best-Selling Brain Supplements — Here's What the Science Actually Says
Pharmacy Times takes a clinical look at Neuriva — the brain supplement endorsed by actress and neuroscientist Mayim Bialik — finding a meaningful gap between the manufacturer's claims around memory, focus, accuracy, and concentration and the evidence underpinning them; none of those claims have been evaluated by the FDA. The review examines all four formulations and identifies which ingredients carry any meaningful research support. If Neuriva is in your stack, read this before you reorder.
Read more →Research & Papers
Klotho Is Longevity's Hottest Protein — But Does the Science Match the Hype?
Robb Report goes deep on Klotho, the naturally produced protein that has emerged as what one researcher calls "the loudest buzzword in age-fighting medicine" — tracking the genetic testing, experimental interventions, and eye-watering price tags now attached to boosting it. Higher Klotho levels are associated with better cognition, improved cardiovascular outcomes, and reduced kidney disease risk, but clinical interventions remain largely experimental and the science is still maturing. A grounded, well-reported read for anyone who's encountered the term at a longevity conference and wondered whether to act on it.
Read more →Your Aging Gut and Liver Are Undermining Each Other — New Research Maps the Loop
Research reviewed in Fight Aging! describes a bidirectional feedback loop between age-related changes in bile acid metabolism — centered in the liver — and the degrading composition of the gut microbiome. The breakdown allows unwanted bacteria and metabolites to leak into the bloodstream, fueling chronic inflammation that drives cardiovascular disease, metabolic dysfunction, and accelerated aging. Animal studies suggest that restoring a younger-profile gut microbiome can partially reverse this damage, raising real questions about what targeted probiotic or prebiotic interventions might achieve in humans.
Read more →Aviado Research: This Week's Deep Dive into Aging Biology
Aviado Research's latest analysis examines emerging findings at the intersection of aging biology and clinical evidence — going deeper on mechanism and methodology than a newsletter summary allows. The full piece includes citations, caveats, and context that puts the science in proper perspective.
Read the full Aviado analysis →Lifestyle & Nutrition
'Longevity-Fixation Syndrome': When Optimizing Your Health Becomes a Mental Health Problem
Jan Gerber, founder of Paracelsus Recovery in Zurich, has named what he's seeing more frequently in his clinic: longevity-fixation syndrome, an unhealthy preoccupation with extending life that manifests as anxiety, social withdrawal, and obsessive health monitoring. Robb Report explores how the booming longevity industry may be generating a new class of wellness disorder — one that quietly erodes quality of life while nominally targeting its extension. If tracking your biomarkers has shifted from empowering to anxiety-inducing, this piece will resonate.
Read more →The Science Is Blunt: No Evidence That Most Longevity Supplements Extend Your Healthspan
A pointed piece in The Conversation argues that the wellness and longevity industries are selling a promise the evidence simply doesn't support — with researchers finding no credible data that most supplements, peptides, or experimental treatments meaningfully extend healthspan. The actual levers, the authors note, remain the unglamorous ones: exercise, diet quality, sleep, and sustained social connection. A useful reality check before you renew that $200-per-month subscription stack.
Read more →Industry & Policy
NMN Market on Track to Hit $1 Billion by 2036 as Regulatory Clarity Drives Demand
The global NMN market — currently valued at $407 million — is projected to reach $1.06 billion by 2036, growing at a 10% CAGR, as regulatory momentum builds around NAD+ precursors. Australia's TGA already approved NMN for dietary supplements late last year, and similar moves in other markets are expected to unlock broader consumer adoption. For anyone watching the NAD+ space, this trajectory signals that NMN's mainstreaming is well underway — with the US and EU regulatory picture the key variable to watch.
Read more →